Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus LERITINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus LERITINE.
ABSTRAL vs LERITINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic